Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

Journal of Urology

Volumn 174, Issue 4 I, 2005, Pages 1242-1247

  Martínez Piñeiro, José A ^a,o   Martínez Piñeiro, Luis ^b   Solsona, Eduardo ^d   Hernández Rodríguez, Rafael ^e   Fernández Gómez, Jesús María ^f   González Martín, Marcelino ^g   Rodríguez Molina, Jesús ^c   Gimeno Collado, Anabel ^h   Flores, Nicolás ⁱ   Isorna, Santiago ^k   Pertusa, Carlos ^j   Rabadán, Mariano ^l   Astobieta, Ander ^m   Camacho, José Emilio ⁿ   Arribas, Salvador ^b   Madero, Rosario ^b  

^a La Luz Clinic   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f Instituto de Investigación Biomédica   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h La Mancha Centro General Hospital   (Spain)

ⁱ HOSPITAL DE BASURTO   (Spain)

^j HOSPITAL DE CRUCES   (Spain)

^k HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^l HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^m HOSPITAL DE GALDAKAO   (Spain)

ⁿ HOSPITAL DE JEREZ   (Spain)

^o UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

more..

Author keywords

Bladder; Bladder neoplasms; Intravesical installation; Mycobacterium bovis

Indexed keywords

BCG VACCINE;

ADULT; AGE; AGED; ARTICLE; BLADDER CAPACITY; BLADDER CARCINOMA; BLADDER CONTRACTION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TRANSURETHRAL RESECTION;

EID: 24944548274     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000173919.28835.aa     Document Type: Article

References (20)

1. Martínez-Pineiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastian, J. L., Pertusa, C. et al: Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int, 89: 671, 2002
2. Bassi, P., Nicola, P., Spinatdin, R., Carando, R., Pagano, F. and Papagallo, G. L.: Low dose vs standard dose BCG therapy of superficial bladder cancer: final results of a phase 3 randomized trial. Eur Urol, suppl., 35: abstract 152, 1999
3. Morales, A., Nickel, J. C. and Wilson, J. W.: Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol, 147: 1256, 1992
4. Mack, D., Holtl, W., Bassi, P., Brausi, M., Ferrari, P., de Balincourt, C. et al: The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol, 165: 401, 2001
5. Mack, D. and Frick, J.: Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br J Urol, 75: 185, 1995
6. Lebret, T., Gaudez, F., Herve, J. M., Barre, P., Lugagne, P. M. and Botto, H.: Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol, 34: 67, 1998
7. Hurle, R., Losa, A., Manzetti, A. and Lembo, A.: Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology, 54: 258, 1999
8. 1 con 27 mg de BCG semanal durante 6 semanas. Arch Esp Urol, 52: 760, 1999
9. Losa, A., Hurle, R. and Lembo, A.: Low-dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol, 163: 68, 2000
10. Lebret, T., Bohin, D., Kassardjian, Z., Herve, J.-M., Molinie, V., Barre, P. et al: Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol, 163: 63, 2000
11. Cookson, M. S. and Sarosdy, M. F.: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol, 148: 797, 1992
12. Zhang, G. K., Uke, E. T., Sharer, W. C., Borkon, W. D. and Bernstein, S. M.: Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol, 155: 1907, 1996
13. Herr, H. W.: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol, 80: 762, 1997
14. 3 transitional cell carcinoma of the bladder treated with BCG. Br J Urol, suppl., 80: abstract 140, 1997
15. Pansadoro, V., Emiliozzi, P., de Paula, F., Scarpone, P., Pansadoro, A. and Sternberg, C.: Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology, 59: 227, 2002
16. Patard, J. J., Rodríguez, A., Leray, E., Rioux-Leclercq, N., Guille, F. and Lobel, B.: Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol, 41: 635, 2002
17. Shahin, O., Thalmann, G. N., Rentsch, C., Mazzucchelli, L. and Studer, U. E.: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol, 169: 96, 2003
18. Sylvester, R. J., van der Meijden, A. P. M. and Lamm, D. L.: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168: 1964, 2002
19. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol, 163: 1124, 2000
20. Smith, J. A., Jr., Labasky, R. F., Cockett, A. T. K., Fracchia, J. A., Montie, J. E. and Rowland, R. G.: Bladder Cancer Clinical Guidelines Panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol, 162: 1697, 1999